NCT05160584: A Study of Real-Life Current Standards of Care in Participants With RRMM (MoMMent)

• NCT05160584: A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma (MoMMent)

NCT05160584: A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma (MoMMent)

The purpose of this study is to assess in real-life clinical practice, over a 24-month period, the effectiveness and safety of current standard of care (SOC) antimyeloma treatments in participants with previously treated relapsed and/or refractory multiple myeloma.

Sponsor

Janssen Pharmaceutica N.V., Belgium

---

ClinicalTrials.gov Identifier: NCT05160584

Official Title: A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma

First Posted : December 16, 2021

Click here for details on ClinicalTrials.gov

---

Locations

Locations

Europe

Belgium

France

Germany

Netherlands

Italy

Spain

United Kingdom